Sun Pharma shares rise on U.S. acquisition

Tue Dec 18, 2012 12:25pm IST

Related Topics

Stocks

   

REUTERS - Shares in Sun Pharmaceutical Industries(SUN.NS), India's most valued drugmaker, rose as much as 2.5 percent after its unit agreed to buy the generic drugs business of U.S.-based URL Pharma from Japan's Takeda Pharmaceutical Co (4502.T).

This is Sun Pharma's second acquisition in the United States within two months after it decided to buy skin treatment firm Dusa Pharmaceuticals Inc DUSA.O for $230 million.

Sun Pharma did not disclose the deal value and said late on Monday the deal was subject to regulatory approvals.

Upon completion of the deal, Sun Pharma's U.S. subsidiary Caraco Pharmaceutical Laboratories will own and manage URL Pharma's generic assets other than Colchicine, a drug used to treat swelling and pain in certain conditions.

Takeda had acquired URL Pharma for an upfront payment of $800 million in June last year with a provision for possible additional payments based on future performance.

Valued $13.72 billion, shares in Sun Pharmaceutical Industries were up 2.3 percent at 738 rupees by 0610 GMT in a Mumbai market that was up 0.1 percent.

(Reporting by Kaustubh Kulkarni in MUMBAI; Editing by Sunil Nair)

FILED UNDER:

Reuters Showcase

FMC-SEBI Merger

FMC-SEBI Merger

Regulatory shakeup could revive commodities markets   Full Article 

Market Eye

Market Eye

Nifty gains after 2015/16 budget focuses on growth, investment  Full Article 

China Interest Rates

China Interest Rates

China to cut benchmark interest rates by 25 basis points  Full Article 

Excise Duty

Excise Duty

Cigarette makers fall after budget hikes excise duty  Full Article 

Import Tax

Import Tax

India to raise import tax on steel to counter China threat  Full Article 

Greek Debt

Greek Debt

Greece seeks negotiations on ECB bond repayment  Full Article 

Economic Survey

Economic Survey

India in "sweet spot" of lower deficits, more growth  Full Article 

GM Corn

GM Corn

Monsanto says GM corn trial in final stage in India  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage